Home

Reed Vaughn Tuckson

CIK 1511051 · EVP & Chief of Medical Affairs · last filed 2026-03-09

Reed Vaughn Tuckson is an EVP & Chief of Medical Affairs who has filed 54 SEC Form 4 insider transactions across 5 companies since 2011. The most recent filing, for HSIC, was dated Mar 9, 2026. Across all open-market trades the lifetime net is −$22.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $47.6M across reported positions. 13 SEC filings were submitted jointly with UNITEDHEALTH GROUP INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$47.57M

Companies

5

Total Filings

54

Lifetime Open-Market Net

-$22.45M

Filer Profile

Reported Address
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY
REDWOOD CITY, CA 94063
Related Filers
UNITEDHEALTH GROUP INC — 13 joint filings, latest 2012-06-07
HENRY SCHEIN INC — 9 joint filings, latest 2026-03-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
HSIC Director 12,520 $89.81 $1.12M $0 8 2026-03-09
Adverum Biotechnologies, Inc. (ADVM) Delisted Director — $4.36 — $0 6 2025-12-10
CTI BIOPHARMA CORP (CTIC) Delisted Director 0 $9.09 $0 $0 13 2023-06-26
CTI BIOPHARMA CORP (TRGT) Delisted Director 76,666 — — $0 10 2014-01-31
UNH EVP & Chief of Medical Affairs 116,943 $397.14 $46.44M -$22.45M 12 2012-06-07

Recent Filings

54 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-09 HSIC Grant (A) +2,577 $0 EDGAR
2025-12-10 Adverum Biotechnologies, Inc. (ADVM) Delisted Disp (D) — $0 EDGAR
2025-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2025-06-12 HSIC Tax (F) −487 -$34.6K EDGAR
2025-03-06 HSIC Mixed +2,272 -$40.2K EDGAR
2024-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2024-03-05 HSIC Mixed +2,109 -$38.1K EDGAR
2023-06-26 CTI BIOPHARMA CORP (CTIC) Delisted Mixed −48,639 -$442.6K EDGAR
2023-06-13 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2023-04-07 CTI BIOPHARMA CORP (CTIC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 54
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.